Infusions are associated with a delay in viral rebound of 5-9 weeks after two infusions, and up to 19 weeks after four infusions, or an average of 6.7 and 9.9 weeks, respectively, compared with 2.6 weeks for historical controls (P < 0.00001). Rebound viruses arise predominantly from a single provirus. In most individuals, emerging viruses show increased resistance, indicating escape. However, 30% of participants remained suppressed until antibody concentrations waned below 20 μg ml −1
, and the viruses emerging in all but one of these individuals showed no apparent resistance to 3BCN117, suggesting failure to escape over a period of 9-19 weeks. We conclude that the administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during analytical treatment interruption in humans.
A fraction of HIV-1-infected individuals develops broad and potent serologic activity against the virus. Single-cell antibody cloning methods 2 have uncovered the source of this activity as broadly neutralizing antibodies (bNAbs), which target different sites on the HIV-1 envelope spike protein, gp160 (refs 1-3) .
In animal models, bNAbs show potent prophylactic activity, suppress established viraemia, and delay viral rebound during analytical treatment interruption (ATI) [4] [5] [6] [7] [8] . In humans, a phase I clinical trial showed that 3BNC117 is generally safe and effective in transiently reducing viraemia in chronically HIV-1-infected individuals 9 . A single infusion of 3BNC117 was well tolerated, rapidly decreased viral loads in viraemic individuals by an average of 1.48 log 10 copies per ml, with durable activity for 4 weeks 9 . In addition, 3BNC117 increased autologous antibody responses in HIV-1-infected individuals, and enhanced clearance of infected cells in humans and in humanized mice 10, 11 . VRC01, a less potent bNAb that also targets the CD4-binding site, suppressed viraemia by 1.14 log 10 (refs 12, 13 and Fig. 1a, b) .
To investigate whether 3BNC117 can suppress viral rebound from the latent reservoir during ATI in chronically suppressed HIV-1 infected humans, we conducted a phase IIa open label clinical trial. To select participants with 3BNC117-sensitive viruses in their latent reservoirs, we performed bulk viral outgrowth cultures of peripheral blood mononuclear cells (PBMCs) from individuals whose viraemia was suppressed by combination antiretroviral therapy (ART). The resulting isolates were screened for sensitivity to 3BNC117 using the TZM-bl assay (Supplementary Table 1 ). Of 63 individuals screened, only 11% yielded viruses that were fully resistant to 3BNC117 (IC 50 > 20 μ g/ml), and 65% were sensitive to 3BNC117 IC 50 at concentrations below 2.0 μ g/ml. In contrast only 29% were similarly sensitive to VRC01 ( Table 1) .
We enrolled HIV-1 infected individuals who were on suppressive antiretroviral therapy (ART) with plasma viral loads < 50 HIV-1 RNA copies per ml for at least 12 months, had CD4 counts > 500 cells per mm 3 , yielded 3BNC117-sensitive outgrowth viruses (IC 50 ≤ 2.0 μ g ml −1 ), and whose viral load at screen was < 20 copies per ml (Extended Data Table 2 ). Two group A participants had viral loads > 20 copies per ml at the time of infusion and were excluded from further analysis (Supplementary Tables 2 and 4 ). Participants are numbered 701-715 (Supplementary Table 2) .
ATI was started 2 days after the first 3BNC117 infusion. ART was reinitiated and infusions were stopped after two consecutive plasma viral load measurements exceeded 200 copies per ml. All individuals on non-nucleoside reverse transcriptase inhibitors (NNRTIs) were switched to an integrase-inhibitor-based regimen (dolutegravir plus tenoforvir disoproxil fumarate/emtricitabine) four weeks before ATI owing to the long half-life of NNRTIs (Supplementary Table 2 ).
Both dosing regimens were generally well tolerated. The majority of reported adverse events were transient and grade 1 in severity (Supplementary Table 5 ). The mean CD4 T-cell count at baseline (day 0) was 747 cells per mm 3 , and the average change in CD4 T-cell counts between start of ATI and rebound was − 127 cells per mm 3 . Although CD4 T cells declined modestly during viral rebound in some participants, CD4 T-cells returned to baseline by week 12 in most participants (mean 828 cells per mm 3 ) (Extended Data Fig. 2 and Supplementary  Table 4 ). Of 12 individuals tested, 5 showed measurable increases in the magnitude and/or breadth of T cell responses to HIV-1 12 weeks after ATI, relative to baseline (Extended Data Fig. 3) . None of the participants experienced acute retroviral syndrome during rebound, and viraemia was re-suppressed below 20 copies per ml in all participants within 2-7 weeks after restarting ART (Supplementary Table 4 ). We conclude that up to four 30 mg kg −1 infusions of 3BNC117 during ATI are generally safe and well tolerated.
By anti-idiotype ELISA 9 the half-life of 3BNC117 during ATI was 19.6 days among group A participants, and 14.1 days among those in group B (Fig. 1e, f and Supplementary Table 4 ). These measurements are similar to previously reported values for 3BNC117 in HIV-1-infected individuals on ART 9 ( Fig. 1e ). All six group A participants maintained viral loads below 200 copies per ml during the first 4 weeks, with rebound 5-9 weeks after ART interruption (Fig. 2a and Supplementary Table 4a ). In group B, rebound occurred 3-19 weeks after ATI, with four out of seven (57%) participants remaining suppressed for at least 10 weeks (Fig. 2b and  Supplementary Table 4b ). The average time to rebound was 6.7 weeks in group A, 9.9 weeks in group B, and 8.4 weeks for all participants together, compared with 2.6 weeks for matched historical non-infused control individuals (Fig. 2c, Extended Data Fig. 4a , Supplementary Tables 4, 6 and 7). Altogether, 6 of the 13 infused individuals (46%) remained suppressed until at least 9 weeks after ATI. Relative to matched historical control individuals, the delay to rebound among all 3BNC117-infused participants was highly significant (P < 0.00001 weighted log-rank test, Fig. 2c, Extended Data Fig. 4 , Supplementary Tables 4, 6 and 7 and Methods). We conclude that repeated infusions of 3BNC117 are generally safe and significantly delay HIV-1 rebound from the latent reservoir during ATI.
Time to viral rebound did not correlate with pre-ATI viral culture sensitivity to 3BNC117, nor to baseline levels of cell-associated HIV-1 DNA (Fig. 2d and Extended Data Fig. 4e ). Therefore the significance of viral outgrowth sensitivity as an inclusion criterion is not clear. 3BNC117 levels at rebound were also variable, ranging from 6-168 μ g ml −1 , but directly correlated with the IC 80 of the emerging virus (Fig. 2a, b, e) .
To determine whether rebound was associated with resistance to 3BNC117, we compared pre-infusion and rebound viral outgrowth cultures. A majority (8/13) of participants had rebound viruses that were more resistant to 3BNC117 (IC 80 > threefold higher, Fig. 3a , c, Extended Data Fig. 5a, Supplementary Table 3 ). Among group A participants, all but one (707) had more resistant rebound viruses; however, among group B participants, four of seven (710, 711, 712 and 715) showed similar pre-infusion and rebound sensitivity to 3BNC117 (Fig. 3a, c, Extended Data Fig. 5a , Supplementary Table 3) . Among these five individuals, 711 was the earliest to rebound at 3 weeks, despite having viruses that were surprisingly sensitive to 3BNC117 as measured by IC 50 (Fig. 2b, Extended Data Fig. 5a , Supplementary Tables 3 and 4) . However, 100% neutralization was not achieved against 711 rebound or pre-infusion viruses, even at high (50 μ g ml ) antibody concentrations, suggesting that 3BNC117 was not fully therapeutic (Extended Data  Fig. 5a, Supplementary Table 3) . Thus, the only participant in the study to rebound within 3 weeks of ATI may have done so because of preexisting resistance to 3BNC117 by the dominant virus in the reservoir.
The other four participants that showed no change between pre-and post-infusion culture sensitivity to 3BNC117, 707, 710, 712, and 715 rebounded relatively late at 9, 19, 16 and 11 weeks after ATI, respectively Tables 3 and 4) . In all of these individuals rebound was associated with relatively low antibody concentrations ranging from 6-41 μ g ml −1 (mean 19.7 μ g ml
−1
). This antibody concentration represents 9.6-fold the mean IC 80 for the rebounding viruses, which is consistent with previous reports on the relationship between suppressive 3BNC117 concentration and neutralization titre in macaques 14 ( Fig Tables 3 and 4) .
To determine whether viral rebound during ATI was associated with resistance to other bNAbs undergoing clinical testing, we examined sensitivity to 10-1074 (ref. 15) , which targets a different and nonoverlapping epitope on the HIV-1 trimer (Fig. 3b, d , Extended Data Table 3 ). With the exception of 703 and 711, the participants' rebound cultures did not show increased resistance to 10-1074. We conclude that rebound during ATI in the presence of 3BNC117 is infrequently associated with increased resistance to 10-1074.
To characterize viruses emerging from the latent reservoir further, we performed single genome sequencing (SGS) of viral RNA from the plasma and viral outgrowth cultures from eight individuals. Phylogenetic analysis of these sequences indicated that all of these eight trial participants were infected with epidemiologically unrelated viruses (Extended Data Fig. 6 ). Given the limited sampling of the pre-infusion reservoir, rebound viruses did not always fall within the radiation Table 1) . The y-axis shows the fraction of viral outgrowth culture supernatants neutralized by a given antibody concentration (x-axis) in Tzm-bl assays. Red line indicates cut-off IC 50 (2 μ g ml −1 ) for participation in the trial. c, d, Diagrammatic representation of study groups A and B respectively. 3BNC117 infusions indicated by the red arrows, and sampling for PK and virologic studies indicated below. Numbers indicate study weeks. e, f, 3BNC117 levels as determined by ELISA for group A (n = 6, left panel, red), group B (n = 7, right panel, red (n = 4), black (n = 2) and purple (n = 1)), HIV-1 negative (n = 3, blue) and viraemic individuals (n = 6, green) 9 . Curves indicate mean 3BNC117 levels, error bars indicate standard deviation. Arrows indicate 3BNC117 infusions.
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of pre-infusion viral isolates (Fig. 3e , f, Extended Data Figs 7 and 8, Supplementary Figs 1 and 2) .
Remarkably, in five of eight participants, all rebounding virus sequences clustered within a low diversity lineage, consistent with the clonal expansion of a single recrudescent virus (Fig. 3e, Table 8 ). These data contrast with individuals undergoing ATI in the absence of antibody infusion, where virus rebound is consistently polyclonal, indicating the activation of multiple latently infected cells [16] [17] [18] [19] . Thus, in addition to delaying rebound, 3BNC117 appears to restrict the outgrowth of viral genotypes from the latent reservoir.
Six of eight participants sequenced had rebound viral outgrowth culture and/or plasma sequences that indicated 3BNC117 resistance. For example, in 704, all rebound viruses carried a serine at position 456 ( Fig. 4a and Supplementary Figs 1 and 2) , which may disrupt a highly conserved salt bridge that maintains the V5 loop's position and conformation [20] [21] [22] . Similarly, in 708 and 709, nearly all rebound viruses carried atypical residues at position 282, where a lysine residue typically forms a salt bridge with 3BNC117 ( Fig. 4a and Supplementary  Figs 1 and 2) 
23
. However, documented 3BNC117 resistance mutations 24 were not universally identified among rebound viral strains ( Fig. 4a and Supplementary Figs 1 and 2) . Only a minor fraction (3 of 23) of sequences in the rebound population of participant 701 had potential resistance-conferring residues in Loop D (274F, 282R), while the remaining sequences did not ( Fig. 4a and Supplementary Figs 1 and 2) . Similarly, in 702 and 703, only a subset of rebound viruses carried a putative resistance-conferring A281D change 1, 23 . Nevertheless, the frequency of this change increased markedly with time in both participants, indicating continued selection for 3BNC117 resistance ( Fig.  4a and Supplementary Figs 1 and 2 ). For participants 707 and 711, no sequence features were identified that would indicate 3BNC117 resistance.
To determine the sensitivity of rebound viruses to 3BNC117, we performed TZM-bl neutralization assays using pseudoviruses typed with SGS Env genotypes ( Table 9 ). With the exception of participant 707, who rebounded 9 weeks after ATI at very low 3BNC117 titres, Env genotypes at rebound were more resistant to 3BNC117 than pre-ATI (Fig. 4b , Extended Data Figs 7 and 8 and Supplementary Table 9 ). We conclude that viral rebound during ATI in the presence of 3BNC117 selects for the emergence of resistant variants, indicating strong selection pressure by this antibody on viral populations arising from the reservoir.
Antibody potency and half-life are directly correlated with HIV-1 prophylaxis in pre-clinical models. For example, VRC01, a CD4bs antibody that is less potent than 3BNC117 1 , is less effective than 3BNC117 in preventing SHIV AD8 infection in macaques 8, 25 . Consistent with these observations, clinical trials with combinations of three less-potent Table 6) , and the combination of all 13 participants (red) who underwent ATI with 3BNC117 infusions. The y-axis indicates the percentage of participants with viral levels below 200 RNA copies per ml, x-axis indicates weeks after ATI initiation. The P value is based on a bootstrap version of the weighted log-rank test adjusting for the potential confounders 'years on ART' , and 'age' (Supplementary Table 7 , Methods Statistical Analyses). d, Dot plot indicating the relationship between 3BNC117 sensitivity of pre-infusion outgrowth cultures at screening (y-axis, IC 80 in μ g ml −1 ) and the week of rebound (x-axis). Group A (n = 6) and group B (n = 7) participants are coloured red and blue respectively. The P value was derived from calculating the Pearson correlation coefficients. e, Dot plot indicating the relationship between 3BNC117 sensitivity of rebound outgrowth cultures (y-axis, IC 80 in μ g ml −1 ) and the 3BNC117 serum concentration at rebound (x-axis, in μ g ml −1 ). 704, 708, 709 and 713 did not reach IC 80 at the concentrations tested and were assigned a value of 22 μ g ml −1 . Group A (n = 6) and group B (n = 7) participants are coloured red and blue, respectively. The P value was derived from calculating the Pearson correlation coefficients. Table 8 ). Pre-ATI culture sequences were inferred as described in the Methods section 'Statistical analyses' . Letter reSeArCH
first-generation bNAbs showed limited effects on viral rebound in the setting of ATI in chronically infected individuals 26, 27 . In addition, selective pressure as evidenced by escape mutations was only observed for one of the three antibodies used in the combination, 2G12 26, 27 . In contrast, 3BNC117 alone significantly delayed viral rebound with nearly half of all individuals remaining below 200 copies per ml until at least 9 weeks, including four individuals who failed to develop resistance and only rebounded at low antibody concentrations. We speculate that the difference in efficacy between 3BNC117 and less potent bNAbs in the setting of ATI is due to increased potency and/or a longer half-life 1, 9, 13 . Nevertheless, the majority of the individuals we studied rebounded at high 3BNC117 serum concentrations. A single viral genotype displaying increased resistance to 3BNC117 established rebound in most cases. These viruses represent pre-existing dormant variants that emerged from the latent reservoir. The time to rebound did not correlate with the amount of viral DNA in circulating PBMCs; however, this is a poor measure of the HIV-1 reservoir, since most integrated proviruses in patients on ART are defective 28 . Instead, the delay in viral rebound may represent a measure of the frequency of 3BNC117-resistant variants in the latent reservoir.
Combinations of drugs are needed to maintain HIV-1 suppression in effective ART regimens. Similarly, combinations of antibodies were required to suppress viraemia in humanized mice 6, 7 . We speculate that combinations of bNAbs will also be needed to increase the frequency of individuals that remain suppressed by antibody during ATI.
Whether 3BNC117 can also impact the size and composition of the latent reservoir during ATI will require additional studies. Supplementary Information is available in the online version of the paper. 
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MethOdS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.
Study design.
An open-label, dose-escalation phase 2a study was conducted in HIV-1-infected participants (http://www.clinicaltrials.gov; NCT02446847). Study participants were enrolled sequentially according to eligibility criteria. Group A received 3BNC117 on days 0 and 21 at a dose of 30 mg/kg body weight at a rate of 250 ml/hour. Group B received 3BNC117 on days 0, 14, 28 and 42 at a dose of 30 mg/kg, as long as viral rebound did not occur. Antiretroviral therapy (ART) was discontinued 2 days after the first 3BNC117 infusion (day 2). Plasma HIV-1 RNA levels were monitored weekly, and ART was resumed when viral load increased to ≥ 200 c.p.m. in two consecutive weekly measurements. Study participants were followed for 36 weeks after the first infusion. Safety data are reported until week 36 for participants enrolled in group A and until week 14 for participants enrolled in group B. All participants provided written informed consent before participation in the study and the study was conducted in accordance with Good Clinical Practice. The protocol was approved by the Federal Drug Administration in the USA and the Institutional Review Board at the Rockefeller University. Study participants. All study participants were recruited at the Rockefeller University Hospital, New York, USA. Eligible participants were adults aged 18-65 years, HIV-1-infected and before enrolment had plasma HIV-1 RNA levels < 50 c.p.m. for at least 12 months while on combination ART and < 20 c.p.m. at the screening visit, and current CD4 count > 500/μ l. In addition, participant-derived HIV-1 isolates produced by co-culture of participant PBMCs with HIV-uninfected donor PBMCs were required to be neutralized by 3BNC117 with an IC 50 < 2 μ g/ml in TZM-bl neutralization assays, as previously described 31 . An IC 50 of < 2 ug/ml was chosen as a cut-off based on previous PK data of 3BNC117 in humans 9 and data in macaques showing that antibody levels 10-100 times the IC 50 value against infecting viral strains are necessary to control viral rebound 14 . However, given the limited diversity and representation of the latent reservoir in outgrowth cultures ( Supplementary Fig. 2 ) and the fact that no correlation between preinfusion IC 50 and delay of viral rebound was found in this study, the significance of this criterion is unclear. Participants on an NNRTI-based ART regimen were switched to a study-provided integrase-inhibitor-based regimen (dolutegravir (Tivicay, ViiV Pharmaceuticals) + tenofovir disoproxil fumarate/emtricitabine (Truvada, Gilead Sciences) 4 weeks before treatment interruption due to the prolonged half-life of NNRTIs. Exclusion criteria included history of CD4 nadir < 200 cells/μ l, concomitant hepatitis B or C infections, previous receipt of a monoclonal antibody of any kind, or clinically relevant physical findings, medical conditions or laboratory abnormalities. Pregnant and breastfeeding women were not eligible. Historical controls (ACTG trial participants). Viral rebound data from 52 participants who participated in four ACTG ATI studies without additional interventions (ACTG 371 32 , A5024 33 , A5068 34 , and A5197 32 ) were compared with viral rebound data in this study. Historical controls were selected based on similar inclusion criteria: age 18-65, Plasma HIV-1 RNA < 50 c.p.m. for at least 12 months before ATI while on combination ART, CD4 count at time of ATI > 500 cells/μ l, CD4 nadir > 200 cells/μ l, weekly viral load measurements at least until viral rebound occurred. Study procedures. The appropriate volume of 3BNC117 was calculated according to body weight, diluted in sterile normal saline to a total volume of 250 ml, and administered intravenously over 60 min. Study participants received 3BNC117 on days 0 and 21, or 0, 14, 28, and 42 and remained under monitoring at the Rockefeller University Hospital for 4 h after each infusion. Participants returned for frequent follow up visits for safety assessments, which included physical examination, measurement of clinical laboratory parameters such as haematology, chemistries, urinalysis, and pregnancy tests (for women). Plasma HIV-1 RNA levels were monitored weekly during the ATI period and CD4 counts were measured every other week (Supplementary Table 4 ). Study investigators evaluated and graded adverse events according to the DAIDS AE Grading Table and determined causality. Blood samples were collected before and at multiple times after 3BNC117 infusions. Samples were processed within 4 h of collection, and serum and plasma samples were stored at − 80 °C. PBMCs were isolated by density gradient centrifugation. The absolute number of peripheral blood mononuclear cells was determined by an automated cell counter (Vi-Cell XR; Beckman Coulter), and cells were cryopreserved in fetal bovine serum plus 10% DMSO. ART re-initiation criteria. Antiretroviral therapy was discontinued 2 days after the first 3BNC117 infusion (day 2). ART was re-initiated when HIV-1 RNA levels were found to be ≥ 200 c.p.m. and/or CD4 T cell counts decreased to < 350 cells/μ l and the result was confirmed with a repeat measurement.
Plasma HIV-1 RNA Levels. HIV-1 RNA levels in plasma were measured at the time of screening (within 49 days before the first infusion), day 0 (before infusion), and weekly until week 12, then at weeks 14, 24 and 36. Participants that remained virologically suppressed to < 20 c.p.m. off ART beyond week 12, returned for weekly measurements of plasma HIV-1 RNA levels. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay, Version 2.0, which detects between 20 and 1 × 10 7 c.p.m. This assay was performed at LabCorp.
CD4
+ and CD8 + T cells. CD4 + and CD8 + T-cell counts were determined at screening, on day 0 (before infusion), and weeks 2, 3, 4, 6, 8, 10, 12, 14, and 36 by a clinical flow cytometry assay, performed at LabCorp. Cells were analysed by flow cytometry. Leukocytes were determined as CD45 + cells. Percentage of cells positively stained for CD3, CD4, CD8 as well as the CD4/CD8 ratio were analysed with the BD Multiset software (BD Biosciences). 3BNC117 study drug. 3BNC117 is a recombinant, fully human IgG1κ mAb recognizing the CD4 binding site on the HIV-1 envelope 1 . The antibody was cloned from an HIV-1-infected viraemic controller in the International HIV Controller Study 1, 35 , expressed in Chinese hamster ovary cells (clone 5D5-5C10), and purified using standard methods. The 3BNC117 drug substance was produced at Celldex Therapeutics Fall River (MA) GMP facility, and the drug product was fill-finished at Gallus BioPharmaceuticals (NJ). The resulting purified 3BNC117 was supplied as a single use sterile 20 mg/ml solution for intravenous injection in 8.06 mM sodium phosphate, 1.47 mM potassium phosphate, 136.9 mM sodium chloride, 2.68 mM potassium chloride, and 0.01% polysorbate 80. 3BNC117 vials were shipped and stored at 4 °C. Measurement of 3BNC117 serum levels. Serum levels of 3BNC117 were determined by a validated sandwich ELISA at Celldex Theapeutics as described previously 9 . Plates (Sigma-Aldrich PN: CLS3590 96-well, High Bind, polystyrene) were coated with 4 μ g/ml of an anti-idiotypic antibody specifically recognizing 3BNC117 (anti-ID 1F1 mAb), and incubated overnight at 2-8 °C. After washing, plates were blocked for 1 h with 5% BSA. Serum samples, QCs and standards were added (1:50 minimum dilution in 5% BSA) and incubated for 1 h at room temperature. 3BNC117 was detected using an HRP-conjugated mouse antihuman IgG kappa chain specific antibody (Abcam PN: ab79115) and the HRP substrate tetra-methylbenzidine. 3BNC117 concentrations were then interpolated from a standard curve of 3BNC117 using a four-parameter logistic curve-fitting algorithm. The reference standard and positive controls were created from the drug product lot of 3BNC117 used in the clinical study. Pharmacokinetic analysis. Blood samples were collected immediately before and at the end of infusions as well as on the day after infusion, weekly during the ATI period and at weeks 14, 24 and 36. 3BNC117 serum levels were measured by ELISA (Celldex Therapeutics). Neutralization assay. Serum samples, viral supernatants, and control antibodies were tested against HIV-1 envelope pseudoviruses as previously described 36, 37 .
Cell-associated HIV-1 DNA. Participant's CD4
+ T-cells were isolated from 10 million cryopreserved PBMCs by negative magnetic selection (Miltenyi). Total DNA was extracted and quantitative PCR performed using pol-and CCR5-directed primers as previously described 7 . Virus cultures. Autologous virus was retrieved from HIV-1 infected individuals as previously described 31 . Briefly, healthy donor PBMCs were obtained by leukapheresis from a single donor. Cells were cultured at a concentration of 5 × 10 6 /ml in Iscove's Modified Dulbecco's Medium (IMDM; Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone, Thermo Scientific), 1% penicillin/ streptomycin (Gibco), and 1 μ g/ml phytohemagglutinin (PHA; Life Technologies) at 37 °C and 5% CO 2 . After 2-3 days, 5 × 10 6 CD8 + depleted cells were transferred into IMDM supplemented with 10% FBS, 1% penicillin/streptomycin, 5 μ g/ml polybrene (Sigma), and 100 U/ml of IL-2. Cells were then co-incubated with 4-8 × 10 6 CD4 + T cells from the study participants and 10 million irradiated healthy donor PBMCs that had been cultured together for 24 h prior in IMDM supplemented with 10% FBS, 1% penicillin/streptomycin, 100 U/ml IL-2 and 1 μ g/ml PHA at 37 °C and 5% CO 2 . Lymphoblasts were replenished weekly by adding 3 million healthy donor PHA stimulated CD8 + depleted lymphoblasts. Culture supernatants were quantified using the Alliance HIV-1 p24 Antigen ELISA kit (PerkinElmer) according to the manufacturer's instructions. TCID 50 s were determined for all HIV-1 containing supernatants 36, 37 and then tested for sensitivity against 3BNC117 and other bNAbs in a TZM.bl neutralization assay. Blood samples and leukapheresis were collected under separate IRB-approved protocols and after volunteers provided informed consent. Sequence analysis. HIV-1 RNA extraction and single genome amplification was performed as described previously 38 . In detail, HIV-1 RNA was extracted from plasma samples using the Qiagen MinElute Virus Spin kit (Qiagen) followed by first strand cDNA synthesis using SuperScript III reverse Letter reSeArCH transcriptase (Invitrogen Life Technologies) and the antisense primer env3out 5′ -TTGCTACTTGTGATTGCTCCATGT-3′ . gp160 env was amplified using envB5out 5′ -TAGAGCCCTGGAAGCATCCAGGAAG-3′ and envB3out 5′ -TTGCTACTTGTGATTGCTCCATGT-3′ in the first round and second round nested primers envB5in 5′ -CACCTTAGGCATCTCCTATGGCAGGAAGAAG-3′ and envB3in 5′ -GTCTCGAGATACTGCTCCCACCC-3′ . PCRs were performed using a High Fidelity Platinum Taq (Invitrogen) at . Logograms were generated using the Weblogo 3.0 tool 40 . Pseudovirus generation. Selected SGS from virus culture supernatants and plasma were used to generate pseudoviruses and tested for sensitivity to bNAbs in a TZM.bl assay 41 . To produce the pseudoviruses, plasmid DNA containing the cytomegalovirus (CMV) promoter was amplified by PCR using forward primer 5′ -GTTGACATTGATTATTGACTAG and reverse primer 5′ -CTTCCTGCCAT AGGAGATGCCTAAAGCTCTGCTTATATAGAC-CTC. The CMV promoter amplicon was fused to individual env SGS amplicons by PCR using forward primer 5′ -AGTAATCAATTACGGGGTCATTAGTTCAT and reverse primer 5′ -ACTTTTTGACCACTTGCCACCCAT. Fusion PCR was carried out using the Expand Long Template PCR System (Roche) in a 60 μ l reaction consisting of 1 ng purified CMV promoter amplicon, 0.125 μ l unpurified env SGA amplicon, 200 nM forward and reverse primers, 200 μ M dNTP mix, 1× Buffer 1, and 1 μ l DNA polymerase mix. PCR was run at 94 °C for 2 min; 25 cycles (94 °C for 12 s, 55 °C for 30 s, 68 °C for four minutes); and 72 °C for 10 min. Resulting amplicons were analysed by gel electrophoresis, purified without gel extraction, and co-transfected with pSG3Δ env into HEK293T cells to produce pseudoviruses as described previously 41 . Statistical analyses. Adverse events were summarized by the number of participants who experienced the event, by severity grade according to the DAIDS AE Grading Table and by relationship to 3BNC117 as determined by the investigator. PK-parameters were estimated by performing a non-c ompartmental analysis (NCA) using WinNonlin 6.3. Kaplan-Meier survival curves were used to compare time to rebound in trial participants to participants in previous ATI studies conducted by ACTG
29
. To exclude the possibility that the observed delay in rebound is confounded by clinical factors, we compared the clinical variables between the control (ACTG trial participants) and treated group using a twosided Fisher's Exact test for categorical variables (gender and CD4 Nadir) and an unpaired Wilcoxon test (two-sided) for continuous variables (age, years on ART and CD4 count before ATI initiation) (Supplementary Table 7 ). Additionally, we tested for each potential confounder whether the variable is predictive for the rebound time. Therefore, we built a univariate survival regression model for each potential confounder and compared those models to a null model using a likelihood ratio test (LRT), which determines how much better the more complex model explains the data than the less complex model. Confounders were considered significant if the model with the potential confounder had an LRT P value of 0.05 or less, which was the case for 'years on ART' as well as 'age' for the comparison between the controls and the combined treatment group (Supplementary Table 7 ). We did not perform a standard Cox regression, since the proportional hazards assumption was not fulfilled for some of the variables. Rebound time was modelled using a log-normal distribution, which resulted in the best model fit as measured by Akaike information criterion (AIC) among several different distributions (Extended Data Fig. 4b-d) . To determine the effect of the treatment after adjusting for the discovered confounders, we performed a weighted log-rank test 42 . Therefore, for each sample inverse probability weights based on the discovered confounders were estimated, which were used to re-weigh the variables of the log-rank statistic. We performed a bootstrapped version of the weighted log-rank test, as recommended in ref. 42 owing to the small sample size. We estimated the class probabilities using a lasso logistic regression model trained with the Matlab function lassoglm with five lambda values in a threefold crossvalidation. To improve stability, the optimal lambda for the lasso logistic regression was determined only once using the original labels and used in all bootstrap runs to train the models that estimate the class probabilities.
Additionally, we performed an LRT at significance level α = 0.05 based on a parametric survival regression model adjusted for the discovered confounders. In this analysis the treatment group still significantly predicted the delay in rebound (Supplementary Table 7) . For the analyses, the R (version 3.2.1) packages survival (version 2.38-3) and fitdistrplus (version 1.0-6) were used and Matlab (version R2015b) for implementation of the weighted log-rank test.
Sequence and phylogenetic analysis. Nucleotide alignments were generated using ClustalW (v.2.11) 43 and manually adjusted using Geneious R8 (v.8.1.6) 39 and MacClade (v.4.08a) 44 . Sites that could not be unambiguously aligned were removed for all phylogenetic analyses. Optimal evolutionary model classes were determined using jModelTest (v.2.1.4) 45 . Maximum likelihood phylogenetic trees were generated using PhyML (v.3) 46 with joint estimation of evolutionary model parameter values and phylogenies. The tree comparing all participants was midpoint rooted and each within-subject tree was rooted on the basal branch as determined by the between-subject tree. Sequences with premature stop codons and frameshift mutations that fell in the gp120 surface glycoprotein region were excluded from all deduced protein analyses.
Sequences generated from the supernatants of viral outgrowth assays represented viruses that were present in the latent reservoir. Per assay, 4-8 million CD4
+ T cells were activated. In an HIV-infected person who is completely suppressed on antiretroviral therapy, it has been determined that 1 × 10 −6 resting CD4 cells are latently infected with replication-competent virus 47 . Thus, one would expect to identify up to eight distinct viral isolates per individual culture. Single genome sequencing of the culture supernatants revealed sets of clonally related sequences, which appear as 'rakes' in a phylogenetic tree (Extended Data Figs 7  and 8 ). The most recent common ancestor of these rakes represents the reactivated virus that was present in the host (similar to the inference of infectious molecular clones as described in ref. 48) . As shown in Extended Data Figs 7 and 8, sequences from culture reactions fall in 1-3 rakes within a given individual. We inferred each rake's most recent common ancestor (MRCA) by building a majority-rule consensus and treated it as a single virus from the participant's latent pool. These MRCAs were used to build the phylogenetic trees shown in Fig. 3 .
Because mixed culture isolates replicated for 14 or more days, in vitro recombinants were observed. In vitro recombinants from culture reactions were identified and removed from the data set if they: (i) had two identifiable parental sequences within the same culture reaction; and (ii) exhibited three consecutive informative sites relative to one parent followed by three consecutive informative sites relative to another. We independently verified that a subset of these sequences showed evidence of recombination using the Recco tool (v.0.93) 49 .
Assessment of rebound virus clonality. The Poisson Fitter v2 tool
50 is designed to test if a set of homogeneous sequences exhibits random diversification. If such a set of sequences exhibits a star-like phylogeny and a Poisson distribution of pairwise differences (Hamming distances), it can be inferred that a single virus gave rise to those sequences. Poisson Fitter v2 tests these and other parameters using maximum likelihood methods and performs a χ 2 goodness of fit test to obtain a P value. A nonsignificant P value signifies that the observed Hamming distances adhere to a Poisson distribution and it can be inferred that a single virus gave rise to rebound. Single genome derived env sequences from the plasma at the earliest time point post-rebound from each participant were tested using Poisson Fitter (Supplementary Table 8) . ELISPOT T-cell response analysis. Interferon gamma Elispot assays were performed as described 51 . Briefly, 96-well polyvinylidene plates (Millipore, Bedford, Mass.) were precoated with 0.5 g/ml of anti-IFNγ monoclonal antibody, 1-DIK (Mabtech, Stockholm, Sweden) and previously frozen PBMCs were plated at a concentration of 50,000 to 100,000 cells per well in a volume of 100 μ l of R10 medium (RPMI 1640 (Sigma), 10% fetal calf serum (Sigma), 10 mM HEPES buffer (Sigma)) with antibiotics (2 mM l-glutamine, 50 U of penicillin-streptomycin/ml). Plates were incubated overnight at 37 °C, 5% CO 2 , and developed as described 51 . Cells were tested against a panel of 410 B-clade overlapping 18-mer peptides (OLPs) spanning the entire HIV-1 genome (consensus sequence from 2001). These peptides were used in a matrix system of 11-12 peptides per pool to screen study participants for HIV-specific T cell responses. Confirmation of recognized individual peptides within a peptide pool was undertaken in an additional Elispot assay, as described 52 . Wells containing PBMCs and R10 medium alone were used as negative controls and were run in duplicate on each plate. Wells containing PBMCs and phytohemagglutinin (PHA) served as positive controls. The numbers of spots per well were counted using an automated Elispot plate reader (ImmunoSpot Reader System; Cellular Technology Limited, Shaker Heights, OH). Responses were regarded as positive if they had at least three times the mean number of spot forming cells (SFC) in the two negative control wells and had to be > 50 SFC/10 6 PBMCs (ref. 51, 52) . Table 3 ). For some participants both screen and day 0 cultures were obtained and showed less than threefold variation in IC 50 values. The red dotted line indicates an IC 50 of 2 μ g ml −1 which was used as a threshold for inclusion in the study. Table 4 ). The last available time point was used as re-suppression time point. Red lines indicate the mean value and error bars indicate standard deviation. P values were obtained using a paired t-test comparing the indicated time points. f, Plasma viral loads and CD4 counts in all study participants. 3BNC117 infusions are indicated with red arrows. The left y-axis shows plasma viral loads in RNA copies per ml (black curves), and right y-axis shows absolute CD4 counts in cells per μ l (red curves). Grey areas indicate ART therapy. Fig. 6 ). Bootstrap values ≥ 90% are shown. Names of env sequences used to generate pseudoviruses for 3BNC117 neutralization analysis are indicated along with the respective IC 80 titres in μ g ml −1 . Representative rebound viruses selected in Fig. 4b are marked with red stars (Fig. 4b, Supplementary  Table 9 ). Zero branch length viruses in multi-rebounders 702 and 703 are marked with black stars. Fig. 6) . Bootstrap values ≥ 90% are shown. Names of env sequences used to generate pseudoviruses for 3BNC117 neutralization analysis are indicated along with the respective IC 80 titres in μ g ml −1 . Representative rebound viruses selected in Fig. 4b are marked with red stars (Fig. 4b, Supplementary  Table 9 ). Zero branch length virus in multi-rebounder 709 is marked with a black star.
